34th week of 2009 patent applcation highlights part 34 |
Patent application number | Title | Published |
20090208399 | Method Of Synthesizing Zirconium Phosphate Particles - Zirconium phosphate particles are synthesized by providing a solution of zirconium oxychloride in an aqueous solvent, adding at least one oxygen-containing additive to the solution, the oxygen-containing additive being selected to form a complex with zirconium ions in the solution of zirconium oxychloride and thereby reduce hydration of the zirconium ions, and combining this solution with phosphoric acid or a phosphoric acid salt to obtain zirconium phosphate particles by sol gel precipitation. | 2009-08-20 |
20090208400 | METHOD AND CRUCIBLE FOR DIRECT SOLIDIFICATION OF SEMICONDUCTOR GRADE MULTI-CRYSTALLINE SILICON INGOTS - This invention relates to a method for direct solidification of semiconductor grade multi-crystalline silicon ingots allowing improved control with the solidification process and reduced levels of oxygen and carbon impurities in the ingot, by crystallizing the semiconductor grade silicon ingot, optionally also including the melting of the feed silicon material, in a crucible made of silicon nitride, or in a crucible made of a composite of silicon carbide and silicon nitride, and where the wall thickness of the bottom of the crucible is dimensioned such that the thermal resistance across the bottom is reduced to a level of at least the same order as thermal resistance across the support below carrying the crucible or lower. The invention also relates to crucibles which are made of silicon nitride, or of a composite of silicon carbide and silicon nitride, and where the wall thickness of the bottom of the crucible is dimensioned such that the thermal resistance across the bottom is reduced to a level of at least the same order as thermal resistance across the support below carrying the crucible or lower. | 2009-08-20 |
20090208401 | PROCESS FOR PRODUCING BORON ADDED PURIFIED SILICON - Provided is a process for producing a boron added silicon (purified silicon) in an energy saving mode from a reduced silicon obtained by reducing a silicon halide with a metal aluminium. The production process of the invention comprises reducing a silicon halide with a metal aluminium to give a reduces silicon, heating and melting the resulting reduced silicon, and adding boron thereto followed by solidification for purification under the condition of a temperature gradient provided in one direction in a mold. Preferably, after washed with an acid, the reduced silicon is heated and molten, and boron is added thereto. After the reduced silicon is heated and molten under reduced pressure, boron is added thereto. After heated and molten, the reduced silicon is purified by solidification in one direction, then heated and molten, and thereafter boron is added thereto. | 2009-08-20 |
20090208402 | Process and system for producing commercial quality carbon dioxide from fine particle limestone - The invention features methods and systems for producing commercial quality carbon dioxide (CO | 2009-08-20 |
20090208403 | Novel catalyst to manufacture carbon nanotubes and hydrogen gas - This invention relates primarily to a novel method to manufacture single/multi/fibers carbon filaments (nano tubes) in pure form optionally with antiferromagnetic and electrical property wherein the byproduct is hydrogen gas resulting in reduction of environmental carbon emissions by at least 20%; both carbon filaments and resultant exhaust are useful products. | 2009-08-20 |
20090208404 | HYDROGEN GENERATING METHOD, HYDROGEN GENERATING ALLOY AND METHOD FOR PRODUCING HYDROGEN GENERATING ALLOY - An alloy generating hydrogen easily and safely for a long time is obtained. The alloy is obtained by melting in a blast furnace a first metal composed of one or more metals of Al, Zn and Mg and a second metal composed of one or more metals of Ga, Cd, In, Sn, Sb, Hg, Pb and Bi; and then placing the alloy in a molten state in water to cool the alloy. | 2009-08-20 |
20090208405 | PROCESS FOR MANUFACTURING PREFLUXED METAL OXIDE FROM METAL HYDROXIDE AND METAL CARBONATE PRECURSORS - A method for producing prefluxed metal oxide from a metal salt selected from nickel hydroxide, cobalt hydroxide, mixed nickel-cobalt hydroxide, nickel carbonate, cobalt carbonate, mixed nickel-cobalt carbonate and combinations thereof includes providing a mixture of at least one slag making oxide and a metal salt selected from the group consisting of nickel hydroxide, cobalt hydroxide, mixed nickel-cobalt hydroxide, nickel carbonate, cobalt carbonate, mixed nickel-cobalt carbonate and combinations thereof, blending with a binder, blending in a flux additive to form a slag-making mixture, forming the slag-making mixture into prefluxed agglomerates, and calcining the prefluxed agglomerates to produce a prefluxed metal oxide. An agglomerate is provided which includes a metal salt selected from nickel hydroxide, cobalt hydroxide, mixed nickel-cobalt hydroxide, nickel carbonate, cobalt carbonate, mixed nickel-cobalt carbonate and combinations thereof, a slag making oxide, and a flux additive. An agglomerate is provide which includes a metal oxide selected from nickel oxide and cobalt oxide, and slag, wherein the metal oxide is encapsulated in the slag. | 2009-08-20 |
20090208406 | LOW TEMPERATURE ACTIVATION OF METAL HYDRIDES - Hydrogen storage alloys, especially as newly formed, have often required high temperature (e.g., >700° C.) activation before the solids will absorb an amount of hydrogen normally storable by the composition. Now, such alloys may be activated by a low temperature (typically below zero degrees Celsius) soak in pressurized hydrogen followed by desorption of the hydrogen at a temperature above about 100° C. Such low temperature hydrogen absorption and higher temperature hydrogen desorption may be repeated a few times until the hydrogen storage alloy material readily absorbs and holds hydrogen for release on demand, and subsequent hydrogen refilling. | 2009-08-20 |
20090208407 | HYDROGEN AND ENERGY GENERATION BY THERMAL CONVERSION OF SILANES - The invention relates to a process for preparing hydrogen. According to the invention, monosilane or polysilane is converted to hydrogen at an elevated temperature with steam or oxygen. | 2009-08-20 |
20090208408 | USE OF VCAM-1 LIGANDS FOR DETECTING AND/OR TREATING CARDIOVASCULAR DISEASES - The invention concerns the use of VCAM-1 ligands in medical imagery, in particular for characterizing and/or therapeutic monitoring of cardiovascular diseases and more particularly for detecting vulnerable coronary atheroma. The invention also concerns the use of VCAM-1 ligands for making a medicine for treating a cardiovascular disease. | 2009-08-20 |
20090208409 | ENCAPSULATED NANOPARTICLES FOR COMPUTED TOMOGRAPHY IMAGING - A detection agent, including a polymerized liposome, a lectin, and an imaging agent, can be administered to an animal for the detection of polyps in the lower gastrointestinal tract. | 2009-08-20 |
20090208410 | ED-B FIBRONECTIN AS STRATIFICATION MARKER FOR ANTI-TUMOR DRUGS - The present invention relates to a method for stratifying tumor cells comprising the steps: (a) providing a sample comprising tumor cells to be analysed, (b) contacting said sample with an ED-B fibronectin-specific molecule and assessing the binding thereof to tumor cells in said sample, and (c) stratifying said tumor cells based on the assessment of step (b). | 2009-08-20 |
20090208411 | Cytotoxicity mediation of cells evidencing surface expression of CD44 - This invention relates to the diagnosis and treatment of cancerous diseases, particularly to the mediation of cytotoxicity of tumor cells; and most particularly to the use of cancerous disease modifying antibodies (CDMAB) or derivatives thereof, optionally in combination with one or more chemotherapeutic agents, as a means for initiating the cytotoxic response. The invention further relates to binding assays which utilize the CDMABs of the instant invention. | 2009-08-20 |
20090208412 | Contrast Agents - A contrast agent of the general formula (I): Z | 2009-08-20 |
20090208413 | Registry Method and Control System for Dea Schedule II-V Medicines - The present invention provides compositions and methods for synthesizing labeled drugs. The present invention further provides methods for preventing or stopping prescription drug abuse for all agents registered as a Drug Enforcement Agency (DEA) schedule II through schedule V medications. According to the present invention, methods are provided for monitoring patient compliance with prescribed drug treatment. The present invention also provides methods for facilitating a replacement prescription when a patient is left without access to their prescribed drug. Furthermore, the present invention provides a method to improve employee compliance with an employer's drug policies via either a voluntary or compulsory system for enhanced drug testing. | 2009-08-20 |
20090208414 | METHOD FOR THE USE OF [11C] CARBON MONOXIDE IN LABELING SYNTHESIS OF 11C-LABELLED KETONES BY PHOTO-INDUCED FREE RADICAL CARBONYLATION - Methods and reagents for photo-initiated carbonylation with carbon-isotope labeled carbon monoxide using alkyl/aryl iodides with carbanion precursors pretreated by a base are provided. The resultant carbon-isotope labeled ketones, and pharmaceutical acceptable salts and solvates are useful as radiopharmaceuticals, especially for use in Positron Emission Tomography (PET). Associated kits and method for PET studies are also provided. | 2009-08-20 |
20090208415 | Tropane compounds - The present invention provides novel tropane compounds and methods for their use. | 2009-08-20 |
20090208416 | MONOCLONAL ANTIBODIES AGAINST NKG2A - The present invention relates to methods of treating immune disorders, particularly autoimmune or inflammatory disorders, and methods of producing antibodies and other compounds for use in therapeutic strategies for treating such disorders. Generally, the present methods involve the use of antibodies or other compounds that prevent the stimulation of NKG2A receptors on NK cells, leading to the lysis of dendritic cells that contribute to the pathology of the disorders. | 2009-08-20 |
20090208417 | Detection and Localized Imaging of Cancer Using X-Ray Fluorescent Nanoparticle/Preferential Locator Conjugates - A method for detecting gold or other nanoparticles conjugated to preferential locators commences by contacting tissue suspected of being neoplastic with gold nanoparticle/preferential locator conjugates for a time adequate for the conjugates to bind with the tissue. A beam of gamma photons (such as from, | 2009-08-20 |
20090208418 | SUPERANTIBODY SYNTHESIS AND USE IN DETECTION, PREVENTION AND TREATMENT OF DISEASE - Superantibodies having enhanced autophilic, catalytic, and/or membrane-penetrating properties are prepared by affinity-based conjugation of a photoactivatable organic molecule to a target immunoglobulin. The photoactivatable organic molecule bears a chromophoric aromatic hydrocarbon moiety, which has affinity for the immunoglobulin. Upon photolysis, the organic molecule is covalently linked to the immunoglobulin. A preferred organic molecule is a peptide and a preferred aromatic hydrocarbon moiety is a tryptophan residue. The photoactivatable organic molecule need not bear a purine, pyrimidine or azido group to effect binding to the immunoglobulin and/or photoactivation. The superantibodies can enhance the potency and expand the targeting range of target antibodies. Autophilic superantibodies can promote apoptosis of target cells and/or enhance therapeutic efficacies in the treatment of patients with diseases or disorders responsive to antibody therapy. Exemplary of such diseases are atherosclerosis and cardiovascular disease. Membrane-penetrating superantibodies can prevent apoptosis by binding to intracellular anti-caspase signal proteins. Compositions containing the superantibodies, as well as methods of making and using them, are disclosed. | 2009-08-20 |
20090208419 | Multimodality Imaging of Reporter Gene Expression Using a Novel Fusion Vector in Living Cells and Animals - Novel double and triple fusion reporter gene constructs harboring distinct imagable reporter genes are provided, as well as applications for the use of such double and triple fusion constructs in living cells and in living animals using distinct imaging technologies. | 2009-08-20 |
20090208420 | IRON OXIDE-BINDING PEPTIDES - The invention relates to diagnostic compositions comprising metal oxide particles, especially iron oxide particles, which are coated with binding peptides. The binding peptides bind with high affinity to the metal oxide particles so that the peptide-coated metal oxide particles are suitable for medical applications, for example as contrast media for magnetic resonance imaging. | 2009-08-20 |
20090208421 | Process for preparing a pharmaceutical formulation of contrast agents - The invention relates to a process for preparing a liquid pharmaceutical formulation containing a complex of macrocyclic chelate with a lanthanide and a mol/mol amount of free macrocyclic chelate of between 0.002% and 0.4%, advantageously between 0.02% and 0.3% and very advantageously between 0.025% and 0.25%, the macrocyclic chelate advantageously being chosen from DOTA, NOTA, DOTAGA, DO3A, BT-DO3A, HP-DO3A and PCTA, and is preferably DOTA, the said process comprising the following successive steps:
| 2009-08-20 |
20090208422 | Composition for improving efficiency of drug delivery - Method and composition suitable for administering by direct convective interstitial infusion are disclosed. The method comprises: placing at least one direct convective interstitial infusion catheter in contact with the tissue, and pressuring the composition through the catheter. The composition is in a liquefied form having a viscosity above a predetermined value. The predetermined value is selected so as to improve infusion of the compositions into interstitial volumes of the tissue, while minimizing backflow of the compositions along an outer wall of the catheter or leakage into low resistance paths. It is demonstrated that high viscosity results in higher treatment efficiency. | 2009-08-20 |
20090208423 | Synergistic Insecticidal Composition Containing Chloronicotynyle and Pyrethroids Compounds - A synergistic insecticidal composition is formed containing a Chloronicotynyle compound and a Pyrethroids compound. The Chloronicotynyle compound is provided in an amount preferably ranging from 0.1 to 5.0% by weight of the synergistic insecticidal composition. The Pyrethroids compound is provided in an amount preferably ranging from 1 to 60% by weight of the synergistic insecticidal composition. The synergistic insecticidal composition also preferably includes 35 to 98.90% by weight of conventional agriculturally acceptable carrier(s) and/or excipients. | 2009-08-20 |
20090208424 | COMPOSITIONS AND METHODS FOR DELIVERY OF SOLUTION TO THE SKIN - Compositions and methods for delivery of medicaments to human or animal skin, for example, the scalp, comprising the steps of transporting the medicaments in a volatile carrier solution to a position adjacent to the skin, and atomizing the preparation at said position onto the skin to thereby uniformly distribute the preparation over the scalp thereby improving absorption of the medicament through the skin | 2009-08-20 |
20090208425 | TRANSMUCOSAL ADMINISTRATION OF 2,3-DIMETHOXY-5-METHYL-6-(10-HYDROXYDECYL)-1,4-BENZOQUINONE - Use of idebenone for the preparation of a medicament for transmucosal administration. | 2009-08-20 |
20090208426 | Use of Diacetyl Trimer as an Aromatic and Flavouring Substance - The invention relates to the use of 2,5-diacetyl-3a,5,6,6a-tetrahydro-6a-hydroxy-2,3a,5-trimethylfuro[2,3-d]-1,3-dioxole (diacetyl trimer) of the formula | 2009-08-20 |
20090208427 | Vanillin Acetals and Sensory Stimulant Composition Containing the Same - The invention relates to a sensory stimulant composition containing one or more of vanillin acetals represented by the general formula (1), and a flavor and fragrance composition, a beverage or food product, a fragrance or cosmetic product, a daily utensil product, an oral composition, or a pharmaceutical product containing the sensory stimulant composition with a warming sensation agent or cooling sensation substance, if necessary. Vanillin acetals represented by the general formula (1) show an excellent pungent and/or warming sensation effect and a cooling sensation-emphasizing effect. | 2009-08-20 |
20090208428 | Bioactive Glass - The present invention relates to a bioactive glass comprising strontium and silicon dioxide, processes for the production of the bioactive glass and the use of the bioactive glass in medicine. | 2009-08-20 |
20090208429 | GLOW AND SUNLESS TANNING VIA A HEATED FLOWABLE COSMETIC TRANSFERRED ONTO SKIN - A product and method for tanning or imparting glow to skin is herein described. The product is a package with associated instructions for applying a tanning cosmetic composition to skin dispensed from a heating device. The heated cosmetic composition imparts a more rapid development of color than an identical composition applied at room temperature. | 2009-08-20 |
20090208430 | GLOW AND SUNLESS TANNING COLOR ENHANCEMENT BY CATIONIC COPOLYMERS - A cosmetic composition for sunless tanning or imparting glow to skin is herein described. The composition includes from about 0.1 to about 20% by weight of a tanning agent and from 0.1 to 20% by weight of a crosslinked cationic copolymer having a monomer unit which is a methacryloylethyl or acryloylethyl tri(C | 2009-08-20 |
20090208431 | Topical turmeric skin care products - A topical skin care product is provided that contains therapeutic concentrations of turmeric and other constituents which is colorless upon application to the skin. The product can be used for cosmetic, protective, and healing purposes without staining skin or clothing yellow. | 2009-08-20 |
20090208432 | AH Receptor Antagonists - The invention relates to the field of aryl hydrocarbon receptor (Ah receptor; AhR) antagonists and their uses. | 2009-08-20 |
20090208433 | AH Receptor Antagonists - The invention relates to the field of aryl hydrocarbon receptor (Ah receptor; AhR) antagonists and their uses. | 2009-08-20 |
20090208434 | 3-(4-hydroxy-3-methoxyphenyl)-1-(4-hydroxyphenyl)-1-propanone and its use in cosmetic and pharmaceutical preparations - The present invention concerns applications of the compound of formula 1 | 2009-08-20 |
20090208435 | METHOD OF QUENCHING ELECTRONIC EXCITATION OF CHROMOPHORE-CONTAINING ORGANIC MOLECULES IN PHOTOACTIVE COMPOSITIONS - The photostabilizing electronic excited state energy—particularly singlet state energy from a UV-absorbing molecule has been found to be readily transferred to (accepted by) α-cyanodiphenylacrylate compounds of formulas (I) and (V) having an alkoxy radical preferably in the four (para) position (hereinafter methoxycrylenes) on one or both of the phenyl rings: | 2009-08-20 |
20090208436 | ORANGE PEARLESCENT PIGMENTS - An orange pearlescent pigment comprising a substrate and a first layer containing FeOOH, and a second layer containing Fe | 2009-08-20 |
20090208437 | GLYCOPYRROLATE IN COSMETIC PREPARATIONS - Glycopyrronium bromide, derivatives and/or isomers thereof in combination with one or more active substances selected from a list of substances as recited in the claims and/or in the form of a W/Si emulsion, an O/W gel, a soap gel stick, and/or a surfactant-containing cleansing formula, and corresponding cosmetic preparations, in particular deodorant/antiperspirant preparations. | 2009-08-20 |
20090208438 | TOPICAL DEODORANT COMPOSITION, AND METHOD OF ITS MANUFACTURE AND USE - A topical deodorant composition comprising unrefined Shea butter, sodium bicarbonate, cornstarch, cocoa butter, coconut oil, lavender oil, Clary sage oil, benzoin gum tincture and vitamin E. The topical deodorant composition controls body odor and improves the moisture, texture and appearance of the skin. To prepare the topical deodorant composition, unrefined Shea butter, cocoa butter, coconut oil and vitamin E are mixed over hot water at 100° F.-120° F. Cornstarch and sodium bicarbonate are added over hot water at 100° F.-120° F. Subsequently, lavender oil, Clary sage oil and benzoin gum tincture are added. The mixture is removed from heat, cooled to 75° F. and distributed via a glass jar, solid stick or squeezable tube. | 2009-08-20 |
20090208439 | Agent for Permanent Hair Waving Containing Heterocyclic Mercapto Compound - Disclosed is an agent for permanent hair waving that can realize permanent hair waving even in the neutral to weakly acidic pH range in which irritation particularly to the skin is not significant. The agent for permanent hair waving includes at least one heterocyclic mercapto compound represented by formula (1): | 2009-08-20 |
20090208440 | BIOLOGICAL ENTITIES AND THE USE THEREOF - The present invention provides engineered enzymes generated from protein scaffolds combined with Specificity Determining Regions, the production thereof and the use of said engineered enzymes for research, nutritional care, personal care and industrial purposes. | 2009-08-20 |
20090208441 | PROCESS FOR THE CONTROLLED RADICAL POLYMERIZATION OR COPOLYMERIZATION OF ONE OR MORE MONOMERS IN THE PRESENCE OF AN INITIATOR OF ALKOXYAMINE TYPE - The invention relates to a process for the polymerization of one or more monomers comprising a stage in which the said monomer or monomers is/are brought into contact, in a medium comprising water, with at least one specific initiator of the alkoxyamine type corresponding, for example, to the following formula: | 2009-08-20 |
20090208442 | CATIONIC COPOLYMERS FORMULATED WITH PIGMENTED COSMETIC COMPOSITIONS EXHIBITING RADIANCE WITH SOFT FOCUS - A cosmetic composition is provided which includes a silicone elastomer, a cationic copolymer with monomeric units selected from at least an acryloylethyl tri(C | 2009-08-20 |
20090208443 | CATIONIC COPOLYMER AND STARCHES FORMULATED COSMETIC COMPOSITIONS EXHIBITING RADIANCE WITH SOFT FOCUS - A cosmetic composition is provided which includes a starch, a cationic copolymer having a monomer unit which is acryloylethyl tri(C | 2009-08-20 |
20090208444 | Novel Formulation - A sanitising formulation comprising a solution of an acidic polymer and an anionic surfactant in a liquid vehicle. Suitable acidic polymers are those which include adjacent | 2009-08-20 |
20090208445 | Compositions Comprising Eucalyptol And/Or Ocimene And/Or Farnesol For Use As Bumblebee Pheromones - Compositions comprising eucalyptol and/or ocimene and/or farnesol are provided for use as bumblebee pheromones. The compositions are useful in agriculture to assist in the pollination of angiosperm plant species. Such compositions can attract insects of the genus | 2009-08-20 |
20090208446 | DUB3 as a Cancer Therapy Target - Described is a method of modulating the activation of a Rho, Arf, Rab, Ran or Rap family protein, said method comprising administering to said sample a USP-17 modulator, for example an inhibitor of expression or activity of DUB-3. The invention enables the use of USP-17 modulators in the treatment of metastatic cancer and other conditions. | 2009-08-20 |
20090208447 | Polypeptides - The present invention provides polypeptides having the property of binding to a given Class I pMHC CHARACTERISED IN THAT said polypeptide has a K | 2009-08-20 |
20090208448 | Inhibition of angiogenesis - Cholesterol-uptake-blocking drugs inhibit angiogenesis and are useful to inhibit diseases perpetuated by angiogenesis. Cholesterol reduction with the use of the drugs increases the intratumoral level of thrombospondin-1, an angiogenesis inhibitor. Ezetimibe (Zetia®), a specific cholesterol-uptake blocking drug, also retards the growth of human tumors, most preferably in combination with low-cholesterol diet. The pharmacologic reduction in serum cholesterol retards prostate cancer growth by inhibiting tumor angiogenesis to combat the growth of prostatic tumors which are directly accelerated by hypercholesterolemia. | 2009-08-20 |
20090208449 | Heterocyclic antiviral compounds - Compounds having the formula I wherein R | 2009-08-20 |
20090208450 | METHOD FOR ENHANCING THE EFFICACY OF ANTIGEN SPECIFIC TUMOR IMMUNOTHERAPY - The invention provides a method for the improved processing efficiency of T cell tumor antigen epitopes using bioinformatic means. The proteolytic sites in the generation of 47 experimentally identified HLA-A2.1-restricted immunodominant tumor antigen epitopes was compared to those of 52 documented HLA-A2.1-restricted immunodominant viral antigen epitopes. The amino acid frequencies in the C-terminal cleavage sites of the tumor antigen epitopes, as well as several positions within the 10 amino acid (aa) flanking regions, were significantly different from those of the viral antigen epitopes. These two groups of epitopes may be cleaved by distinct sets of proteasomes and peptidases or similar enzymes with lower efficiencies for tumor epitopes, targeted activation of the immunoproteasomes and peptidases can be achieved that mediate the cleavage of viral epitopes in order to more effectively generate tumor antigen epitopes thus enhancing antigen-specific tumor immunotherapy. | 2009-08-20 |
20090208451 | HALOGEN PHOSPHONATE MONOESTERS - The present invention relates to detection, immobilization, and production of proteolytic antibodies using halogen phosphonate monoester probes, immobilizing reagents, and antigen conjugates. | 2009-08-20 |
20090208452 | Inhibitor of Endogenous Human Interferon-Gamma - The invention relates to an inhibitor of endogenous human interferon-gamma (hIFN-ϝ) in autoimmune diseases, especially in multiple sclerosis. More precisely, the invention relates to inactivated protein derivatives of the hIFN-ϝ with preserved affinity to the hIFN-ϝ receptor. The derivatives represent genetically modified variants of hIFN-ϝ where the C-terminal part of the molecule is either deleted or replaced with a polypeptide sequence of another human protein and a recombinant hIFN-ϝ inactivated by physical or chemical methods. | 2009-08-20 |
20090208453 | High pressure treatment of aggregated interferons - High pressure to treat aggregated interferons, particularly recombinant human interferon-β, to reduce the aggregate content of interferon material. Highly pure, soluble monomeric recombinant interferon-β is prepared in representative embodiments. Multiple strategies may be used in combination that make nonglycosylated IFN-β more amenable to high pressure treatment. It has been found that refolding yields of high pressure treatment can be significantly improved by use of a combination of strategies, including, or example a pre-treatment of the IFN-β that involves solubilizing and then precipitating the protein. This pre-treatment is particularly effective with respect to recombinant IFN-β inclusion bodies recovered from host cells such as | 2009-08-20 |
20090208454 | MODIFIED INTERFERON BETA POLYPEPTIDES AND THEIR USES - Modified interferon beta polypeptides and uses thereof are provided. | 2009-08-20 |
20090208455 | Method for Treating Polyglutamine Expansion Neurodegenerative Diseases - The present invention relates to use of an inducer of Promyelocytic Leukemia protein (PML) expression, and especially PML IV for the manufacture of a medicament intended for the treatment of polyglutamine expansion neurodegenerative diseases. More specifically, the present invention relates to the use of an interferon polypeptide for the manufacture of a medicament intended for the treatment of polyglutamine expansion neurodegenerative diseases. | 2009-08-20 |
20090208456 | Imidazo[4,5-d]pyrimidines, their uses and methods of preparation - The present invention relates to pharmaceutical compositions for the treatment of prevention of viral infections comprising as an active principle at least one imidazo[4,5-c]pyrimidine having the general formula (A), wherein the substituents are described in the specification. The invention also relates to processes for the preparation of compounds according to the invention having above mentioned general formula, their pharmaceutically acceptable formulations and their use as a medicine or to treat or prevent viral infections. | 2009-08-20 |
20090208457 | Tricyclic-Nucleoside Prodrugs for Treating Viral Infections - Disclosed are compounds, compositions and methods for treating viral infections caused by a Flaviviridae family virus, such as hepatitis C virus. | 2009-08-20 |
20090208458 | Transcriptional inhibitor for human k-ras gene - A transcriptional inhibitor for human K-ras gene which comprises one or more proteins selected from the group consisting of a protein having the amino acid sequence represented by SEQ ID NO:1, a protein having an amino acid sequence derived from the amino acid sequence represented by SEQ ID NO:1 by substitution, deletion or addition of one to several amino acids and having an activity of inhibiting the transcription of human K-ras gene, and partial fragment proteins thereof having an activity of inhibiting the transcription of human K-ras gene. This transcriptional inhibitor for human K-ras gene specifically inhibits the transcription and expression of K-ras gene, which is an oncogene, in a human cancer cell. Thus, it can inhibit the proliferation of cancer cells and induce the reversion of cancer cells into normal cells, which makes it usable as an anticancer agent with little side effects on normal cells. | 2009-08-20 |
20090208459 | Methods of treating anemia using recombinant adeno-associated virus virions - The use of recombinant adeno-associated virus (AAV) virions for delivery of DNA molecules to muscle cells and tissue in the treatment of anemia is disclosed. The invention allows for the direct, in vivo injection of recombinant AAV virions into muscle tissue, e.g., by intramuscular injection, as well as for the in vitro transduction of muscle cells which can subsequently be introduced into a subject for treatment. The invention provides for sustained, high-level expression of a delivered nucleotide sequence encoding erythropoietin, and for in vivo secretion thereof from transduced muscle cells such that systemic delivery is achieved. | 2009-08-20 |
20090208460 | Mutant Herpes Simplex Viruses Comprising Nucleic Acid Encoding A Nitroreductase - An herpes simplex virus wherein the herpes simplex virus genome comprises nucleic acid encoding a nitroreductase (NTR) is disclosed. Disclosed herpes simplex viruses are indicated to be useful in the treatment of cancer which may involve gene directed enzyme prodrug therapy. | 2009-08-20 |
20090208461 | RECOMBINANT BACTERIA WITH E.COLI HEMOLYSIN SECRETION SYSTEM AND INCREASED EXPRESSION AND/OR SECRETION OF HLYA, PROCESS OF MANUFACTURING AND USES THEREOF - The invention relates to a recombinant bacterium with | 2009-08-20 |
20090208462 | Methods of Treatment - The invention concerns the use of a nucleic acid encoding a photoactivator in the manufacture of a medicament for inducing photosensitivity in neuronal cells. In particular, the invention concerns the induction of photosensitivity in retinal ganglion cells (RGCs) for restoring sight and/or alleviating blindness in an individual. The invention further concerns vectors, cells and pharmaceutical compositions therefor. | 2009-08-20 |
20090208463 | MESENCHYMAL STEM CELLS AND USES THEREFOR - Methods of treating autoimmune diseases, allergic responses, cancer, or inflammatory diseases in an animal, promoting wound healing, repairing epithelial damage and promoting angiogenesis in an organ or tissue of an animal by administering to the animal mesenchymal stem cells in an effective amount. | 2009-08-20 |
20090208464 | MESENCHYMAL STEM CELL ISOLATION AND TRANSPLANTATION METHOD AND SYSTEM TO BE USED IN A CLINICAL SETTING - A system and method for the percutaneous, autologous transplantation of mesenchymal stem cells and progenitor helper cells (PHC) from bone marrow to degenerated intervertebral discs or joints. This method is designed to be used by operating room staff in a clinical setting to isolate a mesenchymal stem cell population and PHC during the same surgical procedure as transplantation. The method can be used as a two step procedure where cells are harvested, then isolated, then reimplanted at a later time. In addition, experimental techniques are described to determine which bone marrow cells should be removed via negative selection to generate a PHC population most likely to regenerate certain tissue types in-vitro as well as which combination of fibrinogen and hyaluronic acid and which degree of gel maceration provides the best matrix for in-vitro and in-vivo regeneration of joints and intervertebral discs. | 2009-08-20 |
20090208465 | METHOD OF TREATING NEURAL DEFECTS - The present invention provides a therapeutic agent for a nerve injury and a method for treating a nerve injury. One aspect of the invention is the method for treating a nerve injury by administering to a patient with a nerve injury a therapeutic agent for a nerve injury containing a differentiated cell-derived pluripotent cell obtained by forced expression of reprogramming genes such as a combination of the Oct3/4 gene, Sox2 gene, Klf4, and c-myc gene. in a differentiated cell; or cells obtained by inducing the aforementioned differentiated cell-derived pluripotent cells to differentiate into an embryoid body or a neurosphere. | 2009-08-20 |
20090208466 | INK-JET PRINTING OF TISSUES - A method of forming an array of viable cells is carried out by ink-jet printing a cellular composition containing said cells on a substrate. At least two different types of viable mammalian cells are printed on the substrate, the at least two different types of viable mammalian cells selected to together form a tissue. In some embodiments at least three or four different viable mammalian cells are printed on the substrate, the cells selected to together form a tissue. In some embodiments one of the viable mammalian cell types is a stem cell. In some embodiments the method further comprises printing at least one support compound on the substrate, the support compound selected to form a tissue together with said cells. In some embodiments the method further comprises printing at least one growth factor on the substrate, the growth factor selected to cause the cells to form a tissue. | 2009-08-20 |
20090208467 | P27 AND P21 IN GENE THERAPIES - The expansion of a population of stem cells or progenitor cells, or precursors thereof, may be accomplished by disrupting or inhibiting p21 | 2009-08-20 |
20090208468 | SUPPRESSORS OF CpG OLIGONUCLEOTIDES AND METHODS OF USE - The present disclosure relates to oligodeoxynucleotides that suppress an immune response. Methods are disclosed for preventing or treating an immune-mediated disorder, such as, but not limited to, an autoimmune disease, by administering a therapeutically effective amount of a suppressive oligodeoxynucleotide. Also disclosed are methods of suppressing an immune response in a subject by administering a therapeutically effective amount of a suppressive oligodeoxynucleotide. | 2009-08-20 |
20090208469 | Use of Lactobacillus for Treatment of Autoimmune Diseases - The present technology relates to the use of at least one strain of probiotic bacteria selected from | 2009-08-20 |
20090208470 | Microorganisms Having Bad Smell Removal Activity of Organic Waste and Use Thereof - The present invention relates to novel microorganisms having the efficiency of removing an offensive odor from organic waste and the use thereof. More particularly, the novel microorganisms have the effects of preventing or removing the offensive odor from organic waste, killing insects and fungi, preventing decomposition, and promoting digestion and fermentation. The inventive microorganisms have the effects of preventing or removing the offensive odor from organic waste and killing noxious insects and plant pathogenic fungi, can be used as feed additives and antibiotic substitutes, and also are useful for the preparation of fermented healthy foods. | 2009-08-20 |
20090208471 | Isolation and Use of Human Regulatory T Cells - The present invention provides a new method for isolating and enriching human regulatory T cells. The enriched cells are useful in the treatment of autoimmune disease. | 2009-08-20 |
20090208472 | OIL-IN-WATER EMULSION COMPOSITION CONTAINING LICORICE-DERIVED POLYPHENOL - The present invention provides a licorice polyphenol-containing oil-in-water emulsion composition comprising medium-chain triglyceride, a licorice hydrophobic extract comprising, as a main component, licorice polyphenol in a weight ratio relative to the medium-chain triglyceride of 1-50%, and a polyglycerol fatty acid ester comprised of a fatty acid residue having a carbon number of not less than 14. Since the composition of the present invention is superior in transparency, stable to acid and heat, soluble in water, it can be used for food, drink, pharmaceutical product, quasi-drug, cosmetic and the like, which enables efficient supply of a licorice hydrophobic extract such as licorice polyphenol and the like. | 2009-08-20 |
20090208473 | COMPOSITIONS AND METHODS TO MODULATE CELL MEMBRANE RESEALING - Disclosed herein are compositions and methods for repairing cell membranes. In addition, the invention relates to therapeutic compositions comprising nucleotides and/or polypeptides of the invention in combination with a pharmaceutically acceptable carrier, wherein the composition facilitates the repair of cell membranes. Moreover, the invention relates to the treatment and/or prevention of pathological conditions associated with cell membrane damage. | 2009-08-20 |
20090208474 | BIOLOGICAL ENTITIES AND THE USE THEREOF - The present invention provides engineered enzymes generated from protein scaffolds combined with Specificity Determining Regions, the production thereof and the use of said engineered enzymes for research, nutritional care, personal care and industrial purposes. | 2009-08-20 |
20090208475 | MINA53 ASSAYS - The present invention comprises a method for assaying oxygenase activity the method comprising monitoring oxygenase activity of Mina53. | 2009-08-20 |
20090208476 | Compositions and methods to concurrently treat or prevent multiple diseases with cupredoxins - The present invention relates to compositions and methods to administer compositions comprising cupredoxin and/or cytochrome and/or variants, derivatives, truncations and structural equivalents of cupredoxin and cytochrome to treat and/or prevent two or more conditions in a mammalian cell. The invention also relates to compositions and methods to administer compositions comprising cupredoxin and/or cytochrome and/or variants, derivatives, truncations and structural equivalents of cupredoxin and cytochrome to concurrently treat and/or prevent two or more conditions in a patient such as HIV, cancer, malaria and inappropriate angiogenesis. | 2009-08-20 |
20090208477 | Production of high mannose proteins in plant culture - A device, system and method for producing glycosylated proteins in plant culture, particularly proteins having a high mannose glycosylation, while targeting such proteins with an ER signal and/or by-passing the Golgi. The invention further relates to vectors and methods for expression and production of enzymatically active high mannose lysosomal enzymes using transgenic plant root, particularly carrot cells. More particularly, the invention relates to host cells, particularly transgenic suspended carrot cells, vectors and methods for high yield expression and production of biologically active high mannose Glucocerebrosidase (GCD). The invention further provides for compositions and methods for the treatment of lysosomal storage diseases. | 2009-08-20 |
20090208478 | TRANSDUCIBLE POLYPEPTIDES FOR MODIFYING METABOLISM - Methods and compositions for modifying the metabolism of a subject are provided. One embodiment provides a recombinant polypeptide having a polynucleotide-binding domain, a protein transduction domain, and a targeting domain. In a preferred embodiment, the polynucleotide-binding domain includes one or more HMG box domains. | 2009-08-20 |
20090208479 | Compositions and Methods for Effecting the Levels of High Density Lipoprotein (HDL) Cholesterol and Apolipoprotein AI, Very Low Density Lipoprotein (VLDL) Cholesterol and Low Density Lipoprotein (LDL) Cholesterol - Compositions and methods for raising the level of HDL cholesterol and apolipoprotein AI in a patient and for lowering the levels of VLDL cholesterol and LDL cholesterol in a patient, including compositions and methods which effect the expression of a gene, LIPG, which encodes a lipase enzyme that is a member of the triacylglycerol lipase family or which effect the enzymatic activity of the enzyme. | 2009-08-20 |
20090208480 | LONG HALF-LIFE RECOMBINANT BUTYRYLCHOLINESTERASE - The present invention provides for butyrylcholinesterase (BChE) attached to polyethylene glycol (PEG) to form a complex having greatly increased mean residence time (MRT) in the system of an animal following injection thereinto. Also disclosed are compositions of such complexes, methods of preparing these complexes and method for using these complexes and compositions in the treatment and/or prevention of toxic effects of poisons, such as neurotoxins, to which said animals, such as humans, have been, or may become, exposed. | 2009-08-20 |
20090208481 | Proteomic analysis of active multiple sclerosis lesions - The invention provides methods for treating demyelinating inflammatory diseases by administering to the subject an effective amount of an agent that provides activated protein C activity, where the dose is effective to reduce the adverse clinical indicia of the disease. In some embodiments, the patient being treating is of the chronic active plaque type. | 2009-08-20 |
20090208482 | HUMAN OBESITY SUSCEPTIBILITY GENE ENCODING A MEMBER OF THE NEUREXIN FAMILY AND USES THEREOF - The present invention more particularly discloses the identification of a human obesity susceptibility gene, which can be used for the diagnosis, prevention and treatment of obesity and associated disorders, as well as for the screening of therapeutically active drugs. The invention more specifically discloses certain alleles of the contactin associated protein-like 2 (CNTNAP2) gene related to susceptibility to obesity and representing novel targets for therapeutic intervention. The present invention relates to particular mutations in the CNTNAP2 gene and expression products, as well as to diagnostic tools and kits based on these mutations. The invention can be used in the diagnosis of predisposition to, detection, prevention and/or treatment of coronary heart disease and metabolic disorders, including but not limited to hypoalphalipoproteinemia, familial combined hyperlipidemia, insulin resistant syndrome X or multiple metabolic disorder, coronary artery disease, diabetes and associated complications and dyslipidemia. | 2009-08-20 |
20090208483 | ANTIBODY SELECTIVE FOR DR4 AND USES THEREOF - An antibody of the invention interacts with human DR5 or with human DR4 to produce agonistic or antagonistic effects downstream of the receptor including inhibition of cell proliferation and apoptosis. Nucleic acid sequences and amino acid sequences of DR5 and DR4 antibodies have been elucidated and vectors and cells containing and expressing these sequences have been generated. Methods and uses for the antibodies are detailed including treatment of apoptosis-related disease and treatment of dysregulated cell growth. | 2009-08-20 |
20090208484 | R-SPONDIN COMPOSITIONS AND METHODS OF USE THEREOF - The invention provides for a method for screening compounds that bind to and modulate a regulator of Wnt signaling, R-spondin 4. The invention further provides for methods for diagnosing a keratin-related abnormality, such as anonychia congenital, in a subject. The invention also provides for isolated RSPO4 mutant molecules. | 2009-08-20 |
20090208485 | 3-AMINOCYCLOPENTANECARBOXAMIDES AS MODULATORS OF CHEMOKINE RECEPTORS - The present invention is directed to compounds of Formula I: | 2009-08-20 |
20090208486 | Pharmaceutical composition comprising cxcr3 inhibitor - A pharmaceutical composition for the treatment of cancer of which survival and/or metastasis is under the influence of signal transduction mediated by a chemokine receptor CXCR3, which comprises an agent to inhibit CXCR3, and a method of treatment and diagnosis of such cancer. | 2009-08-20 |
20090208487 | Prevention and treatment of synucleinopathic and amyloidogenic disease - The invention provides improved agents and methods for treatment of diseases associated with synucleinopathic diseases, including Lewy bodies of alpha-synuclein in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the Lewy body. The methods are particularly useful for prophylactic and therapeutic treatment of Parkinson's disease. | 2009-08-20 |
20090208488 | Regulation of dendritic cell functions by the DCAL-2 receptor - This invention provides antibodies that specifically bind to DCAL-2 and other DCAL-2 reagents that modulate dendritic cell function. Modulators of the receptor, including modulators that alter DCAL-2 associated signals to and from DCs, can be used to alter dendritic cell function and to enhance or inhibit immune responses to cancer antigens, autoantigens, or pathogens. | 2009-08-20 |
20090208489 | Antibodies That Bind OV064 and Methods of Use Therefor - Antibodies and antigen-binding fragments of antibodies that bind OV064 are disclosed. The antibodies bind an extracellular domain of OV064. Some of the antibodies and antigen-binding fragments bind an epitope on OV064 sufficient to induce internalization. In some embodiments, the antibodies are humanized, chimeric or human. Nucleic acids and vectors encoding the antibodies or portions thereof, recombinant cells that contain the nucleic acids, and compositions comprising the antibodies or antigen-binding fragments are also disclosed. The invention also provides therapeutic and diagnostic methods utilizing the antibodies and antigen-binding fragments provided herein. | 2009-08-20 |
20090208490 | Molecules that are able to inhibit the binding between NGF and the Trka receptor as analgesics with prolonged effect - Use of an anti-NGF antibody capable of inhibiting the binding between NGF and TrkA, capable of blocking the biological activity of TrkA for the preparation of a medicament for treating and/or preventing chronic pain. | 2009-08-20 |
20090208491 | Compositions and Methods for Diagnosing and Treating Cancer - Humanized antibodies that specifically binds to a non-ligand binding region of human Notch1 are described. Also described are methods of treating cancer, the methods comprising administering a therapeutically effective amount of a humanized anti-Notch1 antibody. | 2009-08-20 |
20090208492 | Lyophilized Immunoglobulin Formulations and Methods of Preparation - The present invention relates generally to the field of pharmaceutical formulation of immunoglobulins. Specifically, the present invention relates to stable, lyophilized, high concentration immunoglobulin formulations. This invention is exemplified by a stabilized lyophilized formulation of the recombinant humanized anti-alpha-4 integrin antibody natalizumab. | 2009-08-20 |
20090208493 | Compounds and methods for the selective inhibition of ABCB1, ABCC1 and ABCG2 transporters and the treatment of cancers, especially drug resistant cancers and high throughput flow cytometry assay to detect selective inhibitors - Compounds disclosed which inhibit ABCB1 transporter protein are useful for treating diseases in which ABCB1 transporter protein mediates the disease state, including numerous cancers, including hematopoietic cancers, including various leukemias, especially T-lineage acute lymphoblastic leukemia, as well as cancerous tumors, especially forms which exhibit multiple drug resistance. Pharmaceutical compositions which comprise an inhibitor of ABCB1 transporter protein and at least one additional anticancer agent, optionally in combination with a pharmaceutically acceptable carrier, additive or excipient are another aspect of the present invention. A flow cytometry based, high-throughput screening (HST) assay that quantifies ABCB1 efflux is also disclosed. Methods of identifying inhibitors of ABCB1, ABCG2 and ABCC1 transporter proteins are also disclosed. | 2009-08-20 |
20090208494 | HUMANIZED ANTIBODY MOLECULES SPECIFIC FOR IL-31 - The invention provides humanized mouse anti-human IL-31 antibodies and antibody fragments that are capable of binding IL-31 and thereby neutralizing, inhibiting, limiting, or reducing the proinflammatory or pro-pruritic effects of IL-31. | 2009-08-20 |
20090208495 | ANTI-TUMOR EFFECTIVE PARAMYXOVIRUS - Paramyxovirus from the group APMV3, APMV4, APMV5, APMV6, APMV7, APMV8, APMV9, Mapueravirus and Fer-de-Lance virus are described, which can be used for the production of a medicament for the treatment of tumors. The virus has a selectivity to kill human tumor cells but not human normal differentiated and human normal proliferating cells at the same dose. By genetic engineering the virus can be modified in such a way that one or more genes are added or are replaced by the homologous genes of a related paramyxovirus. By that method the anti-tumor activity of the resulting chimeric virus is enhanced compared to the parental virus. | 2009-08-20 |
20090208496 | HUMANIZED ANTI-CD4 ANTIBODY WITH IMMUNOSUPPRESSIVE PROPERTIES - A humanized antibody derived from mouse monoclonal anti-CD4 antibody B-F5 is able to activate CD25+CD4+ regulatory T cells and is useful for preparing immunosuppressive compositions. | 2009-08-20 |
20090208497 | HUMANIZED ANTI-CD4 ANTIBODY WITH IMMUNOSUPPRESSIVE PROPERTIES - A humanized antibody derived from mouse monoclonal anti-CD4 antibody B-F5 is able to activate CD25+CD4+ regulatory T cells and is useful for preparing immunosuppressive compositions. | 2009-08-20 |
20090208498 | Genetic Products Differentially Expressed In Tumors And The Use Thereof - The present technology relates to the identification of genetic products expressed in association with tumors and to coding nucleic acids for the expressed products. An embodiment of the present technology also relates to the therapy and diagnosis of disease in which the genetic products are aberrantly expressed in association with tumors, proteins, polypeptides and peptides which are expressed in association with tumors, and to the nucleic acids coding for the polypeptides, peptides and proteins. | 2009-08-20 |